Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes
Authors' conclusion
The risk of developing CKD in type 2 diabetes adults with MAFLD was higher, especially if they are below 60 years old. This study underscores the importance of early prevention strategies for MAFLD to reduce the occurrence of CKD in type 2 diabetes adults.
Study context
- Population
- Adults with T2D with at least three health examinations between 2008 and 2015
- Participants
- 3,627 adults
- Exposure
- MAFLD vs no MAFLD
- Outcome
- CKD: eGFR < 60 mL/min per 1.73 m² or 2 or more proteinuria during follow-up
- Follow-up
- Median 10.0 years
Main finding
As reported in the abstract
Incident CKD · median 10.0 years
MAFLD vs No MAFLDHazard ratio (95 % CI)P value
Incident CKD
1.46(1.26–1.70)
P < 0.001Adjusted for confounding factors
1.30(1.11–1.53)
P < 0.001Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | P value | |
|---|---|---|---|
| CKD risk with MAFLD, stratified by ageMAFLDvs No MAFLDAge < 60 years · stratified analysis | 1.58 (1.28–1.95) | P < 0.001 | |
| CKD risk with MAFLD, stratified by ageMAFLDvs No MAFLDStratified analysis | 1.03 (0.79–1.33) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
- Chronic kidney disease (CKD) risk with MAFLD, stratified by age: age ≥60 years (as implied by stratification); P as printed for both
Overall CKD incidence · median 10.0 years
- Developed CKD
- 837 (23.1%)
- Incidence rate
- 244.7 per 10,000 person-years; 95 % CI, 228.4 - 261.8
Original publication
Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes. Diabetes Res Clin Pract. Published 2 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →